The interaction of anticancer therapies with tumor-associated macrophages

By A. Mantovani, P. Allavena. Journal of Experimental Medicine, 2015

595 citations recorded by the source corpus.

Mantovani and Allavena provide a comprehensive review on the effects of conventional anticancer therapies on tumor-associated macrophages.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/ca7c40664efbe8bbe6eab87fd8930cc2f9b570ae

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. F. Clement
2. M. Raes
3. Carine Michiels
4. M. Génin
5. Antoine Fattaccioli

In Oncology

1. F. Clement
2. M. Raes
3. Carine Michiels
4. M. Génin
5. Antoine Fattaccioli

Citations in the corpus

• Sexual Dimorphism in Innate Immunity (2019, unknown): “Indeed, M1- and M2- polarized macrophages are extremes of a continuum in a universe of functional states [53, 54].”
• Progress in tumor-associated macrophage (TAM)-targeted therapeutics (2017, unknown): “Apart from exerting a cytotoxic effect, several chemotherapy drugs modulate macrophage responses to tumor [157,158].”
• M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide (2015, background): “To mimic the communication between cancer cells and TAMs, M0, M1 or M2 macrophages and HepG2 or A549 cancer cells were co-cultured during respectively 16 (HepG2) or 24 (A549) hours, before etoposide exposure for 24 (HepG2) or 16 (A549) hours.”